Income Statement GlaxoSmithKline Pharmaceuticals Limited NSE India S.E.
Stocks
GLAXO
INE159A01016
Pharmaceuticals
|
Delayed
NSE India S.E.
07:05:08 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 2,771.10 INR | +0.06% |
|
-2.05% | +12.03% |
| 08-03 | GSK India first-quarter profit rises on steady vaccine demand | RE |
| 08-03 | GlaxoSmithKline Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 | CI |
| Fiscal Period: March | 2017 (INR) | 2018 (INR) | 2019 (INR) | 2020 (INR) | 2021 (INR) | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 32.78B | 32.52B | 34.54B | 37.49B | 38.22B | |||||
Total Revenues | 32.78B | 32.52B | 34.54B | 37.49B | 38.22B | |||||
Cost of Goods Sold, Total | 13.78B | 13.04B | 13.55B | 14.14B | 13.76B | |||||
Gross Profit | 19B | 19.48B | 20.99B | 23.35B | 24.46B | |||||
Selling General & Admin Expenses, Total | 7.4B | 7.06B | 7.36B | 7.02B | 7.37B | |||||
Depreciation & Amortization - (IS) | 682M | 658M | 697M | 668M | 664M | |||||
Other Operating Expenses | 3.92B | 4.27B | 4.54B | 4.52B | 3.95B | |||||
Other Operating Expenses, Total | 12.01B | 11.99B | 12.59B | 12.21B | 11.98B | |||||
Operating Income | 6.99B | 7.48B | 8.39B | 11.14B | 12.48B | |||||
Interest Expense, Total | -19.96M | -18.12M | -17.99M | -13.14M | -27.32M | |||||
Interest And Investment Income | 717M | 698M | 729M | 763M | 657M | |||||
Net Interest Expenses | 697M | 680M | 711M | 750M | 630M | |||||
Currency Exchange Gains (Loss) | -51.36M | -99.07M | - | -22.66M | -47.64M | |||||
Other Non Operating Income (Expenses) | 37M | 428K | - | - | - | |||||
EBT, Excl. Unusual Items | 7.67B | 8.07B | 9.1B | 11.87B | 13.06B | |||||
Restructuring Charges | -201M | -114M | -1.63B | - | - | |||||
Gain (Loss) On Sale Of Investments | - | 308M | 488M | 696M | 796M | |||||
Gain (Loss) On Sale Of Assets | 3.24M | 278K | 8.89M | -15.13M | -457K | |||||
Asset Writedown | 2.61M | - | - | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | 314M | 104M | 197M | 46.92M | 206M | |||||
EBT, Incl. Unusual Items | 7.79B | 8.36B | 8.16B | 12.6B | 14.06B | |||||
Income Tax Expense | 3.98B | 2.29B | 2.26B | 3.32B | 3.7B | |||||
Earnings From Continuing Operations | 3.81B | 6.08B | 5.9B | 9.28B | 10.36B | |||||
Earnings Of Discontinued Operations | 13.14B | 30.45M | - | - | - | |||||
Net Income to Company | 16.95B | 6.11B | 5.9B | 9.28B | 10.36B | |||||
Net Income - (IS) | 16.95B | 6.11B | 5.9B | 9.28B | 10.36B | |||||
Net Income to Common Incl Extra Items | 16.95B | 6.11B | 5.9B | 9.28B | 10.36B | |||||
Net Income to Common Excl. Extra Items | 3.81B | 6.08B | 5.9B | 9.28B | 10.36B | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 100.04 | 36.05 | 34.83 | 54.76 | 61.15 | |||||
Basic EPS - Continuing Operations | 22.48 | 35.87 | 34.83 | 54.76 | 61.15 | |||||
Basic Weighted Average Shares Outstanding | 169M | 169M | 169M | 169M | 169M | |||||
Net EPS - Diluted | 100.04 | 36.05 | 34.83 | 54.76 | 61.15 | |||||
Diluted EPS - Continuing Operations | 22.48 | 35.87 | 34.83 | 54.76 | 61.15 | |||||
Diluted Weighted Average Shares Outstanding | 169M | 169M | 169M | 169M | 169M | |||||
Normalized Basic EPS | 28.3 | 29.76 | 33.58 | 43.79 | 48.18 | |||||
Normalized Diluted EPS | 28.3 | 29.76 | 33.58 | 43.79 | 48.18 | |||||
Dividend Per Share | 30 | 32 | 32 | 42 | 57 | |||||
Payout Ratio | 29.89 | 249.8 | 91.8 | 80.79 | 68.92 | |||||
Supplemental Items | ||||||||||
EBITDA | 7.43B | 7.88B | 8.81B | 11.53B | 12.86B | |||||
EBITA | 6.99B | 7.48B | 8.39B | 11.14B | 12.48B | |||||
EBIT | 6.99B | 7.48B | 8.39B | 11.14B | 12.48B | |||||
EBITDAR | 7.45B | 7.9B | 8.83B | 11.55B | 12.88B | |||||
Total Revenues (As Reported) | 33.54B | 33.52B | 35.76B | 38.95B | - | |||||
Effective Tax Rate - (Ratio) | 51.12 | 27.35 | 27.72 | 26.38 | 26.32 | |||||
Total Current Taxes | 4.08B | 2.47B | 2.38B | 3.26B | 3.61B | |||||
Total Deferred Taxes | -94.01M | -184M | -114M | 63.39M | 94.57M | |||||
Normalized Net Income | 4.79B | 5.04B | 5.69B | 7.42B | 8.16B | |||||
Interest on Long-Term Debt | 17.37M | 13.98M | 15.75M | 11.79M | 27.22M | |||||
Non-Cash Pension Expense | 7.58M | 8.24M | -1.08M | -3.32M | 112M | |||||
Supplemental Operating Expense Items | ||||||||||
Advertising Expense | 1.28B | 1.09B | 1.09B | 1.2B | 1.28B | |||||
Selling and Marketing Expenses | 1.28B | 1.09B | 1.09B | 1.2B | 1.28B | |||||
Research And Development Expense From Footnotes | 18.28M | 19.1M | 25.44M | 26.12M | 32.2M | |||||
Net Rental Expense, Total | 18.13M | 20.98M | 20.05M | 19.77M | 19.81M | |||||
Imputed Operating Lease Interest Expense | 10.58M | 17.08M | 16.87M | 14.52M | 20.04M | |||||
Imputed Operating Lease Depreciation | 7.54M | 3.9M | 3.18M | 5.25M | -226K | |||||
Maintenance & Repair Expenses, Total | 220M | 192M | 207M | 230M | 246M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 65.45M | 25.33M | 114M | 81.98M | 124M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | - | |||||
Total Stock-Based Compensation | 65.45M | 25.33M | 114M | 81.98M | 124M |
Select your edition
All financial news and data tailored to specific country editions
















